InVivoMAb Anti-Human CX3CL1/Fractalkine Antibody (Iv0091) (HX143010)

Price(USD): $

Spec:

Number:

Overview

Catalog No.	HX143010
Description	InVivoMAb Anti-Human CX3CL1/Fractalkine (Iv0091) [Iv0091] (HX143010) is a human monoclonal antibody detecting Small-inducible cytokine D1 in ELISA, Neutralization. Suitable for Human.
Species reactivity	Human
Applications	ELISA, Neutralization
Host species	Human
Isotype	IgG2, kappa
Clone ID	Iv0091
Clonality	Monoclonal
Target	Small-inducible cytokine D1, Fractalkine, Neurotactin, C-X3-C motif chemokine 1, NTT, CX3CL1, SCYD1, FKN, CX3C membrane-anchored chemokine
Endotoxin level	Please contact with the lab for this information.
Purity	>95% as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P78423
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Note	For research use only. Not suitable for clinical or therapeutic use.

Images

Bioactivity

SEC-HPLC detection for InVivoMAb Anti-Human CX3CL1/Fractalkine (ABV0123).
SDS-PAGE

SDS-PAGE for InVivoMAb Anti-Human CX3CL1/Fractalkine (Iv0091).
Flow CytoMetry

Flow-cytometry using APC anti-human CX3CL1 antibody. HepG-2 cells were stained with an irrelevant antibody (Blue Histogram) or an APC anti-human CX3CL1 monoclonal antibody (Catalog: HX143010, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer.
Flow CytoMetry

Flow-cytometry using PE anti-human CX3CL1 antibody. HepG-2 cells were stained with an irrelevant antibody (Blue Histogram) or an PE anti-human CX3CL1 monoclonal antibody (Catalog: HX143010, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, and cells analysed on a NovoCyte Flow Cytometer.